Nonetheless, recent advances in molecular characterization and diagnostic tools in cancer are gradually leading to the development of combined treatment strategies, associating PI3K/Akt/mTOR inhibitors with therapies targeting compensatory signaling pathways. The gene discussed is PIK3CA; the disease is cancer.